细胞毒性T细胞
免疫系统
CD8型
癌症研究
T细胞
免疫学
免疫疗法
调节性T细胞
肺癌
生物
癌症免疫疗法
医学
白细胞介素2受体
病理
体外
生物化学
作者
Miya Haruna,Azumi Ueyama,Yoko Yamamoto,Michinari Hirata,Kumiko Goto,Hiroshi Yoshida,Naoko Higuchi,Tetsuya Yoshida,Yujiro Kidani,Yurika Nakamura,Morio Nagira,Atsunari Kawashima,Kota Iwahori,Yasushi Shintani,Naganari Ohkura,Hisashi Wada
标识
DOI:10.1038/s41598-022-09458-5
摘要
Regulatory T cells (Tregs) suppress the host immune response and maintain immune homeostasis. Tregs also promote cancer progression and are involved in resistance to immune checkpoint inhibitor treatments. Recent studies identified selective CCR8 expression on tumor-infiltrating Tregs; CCR8+ Tregs have been indicated as a possible new target of cancer immunotherapy. Here, we investigated the features of CCR8+ Tregs in lung cancer patients. CCR8+ Tregs were highly activated and infiltration of CCR8+ Tregs in tumors was associated with poor prognosis in lung cancer patients. We also investigated their immune suppressive function, especially the influence on cytotoxic T lymphocyte cell function. The Cancer Genome Atlas analysis revealed that CD8 T cell activities were suppressed in high CCR8-expressing tumors. Additionally, depletion of CCR8+ cells enhanced CD8 T cell function in an ex vivo culture of lung tumor-infiltrating cells. Moreover, CCR8+ Tregs, but not CCR8- Tregs, induced from human PBMCs markedly suppressed CD8 T cell cytotoxicity. Finally, we demonstrated the therapeutic effect of targeting CCR8 in a murine model of lung cancer. These findings reveal the significance of CCR8+ Tregs for immunosuppression in lung cancer, especially via cytotoxic T lymphocyte cell suppression, and suggest the potential value of CCR8-targeted therapy for cancer treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI